Good news.
There is a new drug in the fight against liver cancer. Most drugs do not work on liver cancer so this is a breakthrough.
The bad news.
Nexavar runs $5,400 per month.
So who pays?
All of us.
So what does the patient gain by using this new drug?
Average life expectancy without the drug . . . 7.9 months.
Average life expectancy for those using the drug . . . 10.7 months.
Is trading $15,000 for 3 months worth it?
This is a question all of us will have to ask.
Friday, July 25, 2008
blog comments powered by Disqus
Subscribe to:
Post Comments (Atom)